Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Rectal Cancer treatment details. Biologic therapy. Memorial Sloan-Kettering Cancer Center, Memorial Sloan-Kettering Cancer Center, United States

Survival: 6.4 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: United States
City/State/Province: Memorial Sloan-Kettering Cancer Center
Hospital: Memorial Sloan-Kettering Cancer Center
Journal: Link
Date: 4/2004

Patients: This Phase II trial involved 57 patients with metastatic colorectal cancer. Patients were required to have received a chemotherapy drug (irinotecan), either alone or in a combination regimen, and to have demonstrated clinical failure on this regimen before becoming involved in this study. In addition, the tumors of all patients had EGFR. (EGFR is epidermal growth factor receptor. It is expressed in many normal tissues and over expressed in some tumors.)

Treatment: Treatment consisted of the monoclonal antibody, cetuximab.

Toxicity: Grade 3-4 toxicities included: acne, allergic reaction, asthenia, atrial fibrillation, confusion, diarrhea, headache, hypokalemia, rash, and vomiting.

Results: Median survival was 6.4 months.

Support: Four of the authors of this study either act as a consultant for Imclone and/or Bristol-Myers Squibb, performed contract work for these companies, served as an officer or board member of these companies, and/or received compensation from these companies. Both Imclone and Bristol-Myers Squibb are involved in the marketing of cetuximab (Erbitux).

Correspondence: Leonard B. Saltz, MD

E-mail to a Friend Email Physician More Information